EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis

被引：0
|
作者：
Herrmann, Tara [1 ]
Hamarstrom, Elaine [2 ]
Ramalingam, Suresh [3 ]
机构：
[1] Medscape Educ, Ft Sam Houston, TX USA
[2] Medscape Educ, New York, NY USA
[3] Emory Univ, Winship Canc Inst, Med Oncol, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
EGFR; T790M; Education; molecular testing;
D O I：
10.1016/j.jtho.2016.11.1716
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-049
引用
收藏
页码：S1218 / S1219
页数：2
相关论文
共 50 条
  • [41] Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match
    Leighl, Natasha B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (07): : 652 - 654
  • [42] Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis
    Ma, Ji-Yong
    Yan, Hai-Jun
    Gu, Wei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (02) : 397 - 402
  • [43] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [44] Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
    Grech, C.
    Hackner, K.
    Strieder, M.
    Buder, A.
    Hochmair, M. J.
    Filipits, M.
    Errhalt, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 578 - 578
  • [45] A prospective observational multicenter study on osimertinib resistance using ctDNA analysis in EGFR-mutated NSCLC
    Osuga, Mitsuo
    Tamiya, Akihiro
    Harada, Daijiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Taniguchi, Yoshihiko
    Nakamura, Keiichi
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2025, 116 : 330 - 330
  • [46] A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US
    Nilsson, J.
    Winfree, K.
    Molife, C.
    Bhattacharyya, D.
    D'Yachova, Y.
    Wang, X.
    Malmenas, M.
    Taipale, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S322 - S323
  • [47] Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
    Zheng, M-M
    Lin, S-H
    Li, Y-S
    Yin, K.
    Li, P.
    Zhang, X-C
    Gao, S-X
    Zhou, Q.
    Tu, H-Y
    Yang, J-J
    Chen, H-J
    Pan, Y.
    Wang, B-C
    Wang, Z.
    Xu, C-R
    Xiao, F-M
    Zhong, W-Z
    Yan, H-H
    Tang, L-B
    Wu, L.
    Zeng, L.
    Liu, S-Y. M.
    Wong, C. C.
    Wu, Y-L
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S80 - S81
  • [48] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kei Kunimasa
    Kazumi Nishino
    Yoshiharu Sato
    Masahide Mori
    Shoichi Ihara
    Hidekazu Suzuki
    Izumi Nagatomo
    Toru Kumagai
    Toshitaka Morishima
    Fumio Imamura
    Scientific Reports, 12
  • [49] Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
    Kunimasa, Kei
    Nishino, Kazumi
    Sato, Yoshiharu
    Mori, Masahide
    Ihara, Shoichi
    Suzuki, Hidekazu
    Nagatomo, Izumi
    Kumagai, Toru
    Morishima, Toshitaka
    Imamura, Fumio
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [50] NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
    Mendes, Cindy
    Lemos, Isabel
    Francisco, Ines
    Almodovar, Teresa
    Cunha, Fernando
    Albuquerque, Cristina
    Goncalves, Luis G.
    Serpa, Jacinta
    LUNG CANCER, 2023, 182
12345